All In Biotech

Drug Trial Radar · NCT01656057

The Impact of Gall Bladder Emptying and Bile Acids on the Human GLP-1-secretion

Last checked: Nov 19, 2026Latest source record: Jul 14, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Jul 2012

Primary completion

Oct 2013

Study completion Apr 2014

Sponsor

Lead sponsor
Filip Krag KnopAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Copenhagen
First posted
Aug 2, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Single group
Masking
Double (participant, investigator)
Primary purpose
Basic science
Who can join
Male only, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The last couple of years it has been shown that bile acids not only acts as simple emulsifiers of fat, but constitutes a complex metabolic integrator which not only have an influence on fat digestion and lipid metabolism, but also modulates the energy expenditure in (brown) adipose tissue and muscle tissue. This action is due to stimulation of the receptor TGR5 by bile acids. Recently scientists have discovered that this receptor in rodents is also expressed on the surface of intestinal L-cells (which normally secrets Glucagon-Like Peptide-1 (GLP-1) in response to nutrient stimulation). The stimulation of this receptor has shown a GLP-1 secretion from the intestinal cells which is interesting since GLP-1 has a central role in maintaining normal glucose tolerance and thus blood sugar. Given the above, bile acids has an important impact on intestinal GLP-1 secretion. Whether these scientific findings can be proven in human beings is uncertain. The primary hypothesis is that stimulating gall bladder emptying via Cholecystokinin (CCK) in healthy subjects will result in a significant GLP-1 response. We also hypothesize that adding orally Metformin or a sequestrant ("a bile acid binder") will further enhance this GLP-1 response.

Conditions

  • To Assess the Impact of Bile Acids on Human Glukagon-like-peptide-1 Secretion

Interventions

  • AcetaminophenDrug

    Acetaminophen dissolved in 50 ml of water

  • MetforminDrug

    Metformin + acetaminophen dissolved in 50 ml of water

  • ColesevelamDrug

    Colesevelam + acetaminophen dissolved in 50 ml of water

  • Cholecystokinin-8Other

    iv. infusion of CCK-8, 24 pmol/kg/hour for the first 60 minutes

  • SalineOther

    iv. saline infusion 40 ml/hour for the first 60 minutes

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. GLP-1 response as incremental area under curve (iAUC)Time frame: -30, -15, 0, 10, 20, 30, 40, 50, 60, 90, 120, 150, 180, 240

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospital of Copenhagen, Gentofte Hospital, Diabetic Research Division

    Copenhagen, Hellerup, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.